DCTH - Delcath Systems Inc

-

$undefined

N/A

(N/A)

Delcath Systems Inc NasdaqCM:DCTH Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Location: 566 Queensbury Avenue, New York, NY, 12804, United States | Website: https://www.delcath.com | Industry: Medical Devices | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

536.3M

Cash

58.9M

Avg Qtr Burn

-1.724M

Short % of Float

2.78%

Insider Ownership

2.61%

Institutional Own.

45.02%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
HEPZATO KIT (melphalan hydrochloride for injection/hepatic delivery system) Details
Liver Dominant metastatic Ocular Melanoma, Metastatic Uveal Melanoma

Approved

Quarterly sales

CHEMOSAT® Details
Uveal melanoma

Phase 2

Update

HEPZATO™ Details
Liver-Dominant Metastatic Breast Cancer

Phase 2

Initiation

HEPZATO™ Details
Metastatic colorectal cancer

Phase 2

Initiation

Failed

Discontinued